Tempest Therapeutics Inc (TPST)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.03-1.90%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TPST
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||||
| Revenues | — | — | — | — | — | — | — | — | — | 0.3 | 0.7 | 0.3 | — | — | — |
| Total Revenues | — | — | — | — | — | — | — | — | — | 0.3 | 0.7 | 0.3 | — | — | — |
| Cost of Revenues | — | — | — | — | — | — | — | — | — | 0.8 | 5.4 | 2.2 | — | — | — |
| Operating Expenses & Income | |||||||||||||||
| Selling, General & Admin | — | — | — | — | — | — | — | — | — | 27.7 | 49.2 | 51.6 | 26.1 | — | — |
| R&D Expenses | — | — | — | — | — | — | — | — | — | 18.3 | 21.6 | 18.4 | 21.8 | 15.8 | 6.3 |
| Operating Income | (40.6) | (26.6) | (42.0) | (29.2) | (34.6) | (27.0) | (19.3) | (45.4) | (26.9) | (84.3) | (81.0) | (72.0) | (47.9) | (29.1) | (13.5) |
| Earnings from Continuing Operations | |||||||||||||||
| Interest Expense | — | 0.2 | 1.3 | 1.4 | 1.6 | 1.3 | 0.0 | — | 0.1 | — | — | — | — | — | — |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | — | — | (0.1) | 0.1 | 0.0 |
| Other Non-Operating Income / Expenses | 0.2 | 0.3 | 0.2 | (0.3) | (1.1) | (1.3) | 0.1 | — | — | — | — | — | — | — | — |
| Asset Writedown | — | — | — | — | — | — | — | — | — | 0.2 | — | 0.0 | 0.4 | 0.4 | — |
| EBT, Incl. Unusual Items | — | — | — | — | — | — | — | — | — | (50.9) | (82.1) | (73.1) | — | — | — |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | — | — | 0.1 | 0.2 | 0.1 | 0.0 | 0.0 | — |
| Net Income | |||||||||||||||
| Minority Interest | — | — | — | — | — | — | — | 0.0 | 0.0 | — | — | — | — | — | — |
| Net Income | (40.5) | (26.3) | (41.8) | (29.5) | (35.7) | (28.3) | (19.2) | (44.6) | (27.2) | (84.6) | (82.3) | (73.2) | (49.5) | (29.0) | (13.5) |
| Per Share | |||||||||||||||
| Basic EPS | (2.66) | (6.33) | (1.50) | (1.91) | (3.09) | (7.47) | (41.03) | — | — | — | — | — | — | — | — |
| Diluted EPS | (2.66) | (6.33) | (1.50) | (1.91) | (3.09) | (7.47) | (41.03) | — | — | — | — | — | — | — | — |
| Dividend per Share | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 15.2 | 4.1 | 27.9 | 15.4 | 11.5 | 3.8 | 0.5 | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 15.2 | 4.1 | 27.9 | 15.4 | 11.5 | 3.8 | 0.5 | — | — | — | — | — | — | — | — |
| Supplemental | |||||||||||||||
| EBITDA | — | — | — | — | — | — | — | — | — | (82.7) | (78.8) | (70.7) | (47.5) | (28.9) | (13.4) |
| EBIT | (40.6) | (26.6) | (42.0) | (29.2) | (34.6) | (27.0) | (19.3) | (45.4) | (26.9) | (84.3) | (81.0) | (72.0) | (47.9) | (29.1) | (13.5) |
| Effective Tax Rate | — | — | — | — | — | — | — | — | — | -0.1% | -0.2% | -0.1% | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.